75
Participants
Start Date
December 28, 2021
Primary Completion Date
September 30, 2024
Study Completion Date
December 31, 2024
APG2575
APG-2575 orally once daily at 600mg dose levels, every 28 days as a cycle.
NOT_YET_RECRUITING
The First Affilated Hospital of Soochow University, Suzhou
NOT_YET_RECRUITING
Institute of blood transfusion of Chinese Academy of Medical Sciences, Tianjin
NOT_YET_RECRUITING
The First Affiliated Hospital of Zhejiang University School of Medicine, Hanzhou
NOT_YET_RECRUITING
The First Affilated Hospital of Nanchang University, Nanchang
RECRUITING
Union Hospital medical college Huazhong University of Science and Technology, Wuhan
NOT_YET_RECRUITING
Henan Cancer Hospital, Zhengzhou
NOT_YET_RECRUITING
Sun Yat-sen University Cancer Center, Guangzhou
NOT_YET_RECRUITING
Zhujiang Hospital of Southern Medical University, Guangzhou
NOT_YET_RECRUITING
Nanfang Hospital of Southern Medical University, Guangzhou
NOT_YET_RECRUITING
Hainan General Hospital, Haikou
NOT_YET_RECRUITING
People's hospital of Jiangsu Province, Suzhou
Lead Sponsor
Ascentage Pharma Group Inc.
INDUSTRY